Indeed, specific targeting of HDAC5 with HDAC5 silencing or a specific HDAC5 inhibitor (LMK-235) was used in an in vivo sepsis model and it resulted in improved mice survival and intestinal permeability, and in a reduced intestinal dysfunction.48 These data strengthen the hypothesis that HDAC5 inhibition could represent an interesting therapeutic alternative in the treatment of intestinal diseases. This evidence concerns the gene HDAC5 and intestinal disorder.